REG - Medpal AI PLC - Vertically Integrated Healthcare Model

Medpal AIAnnouncement

10/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260210:nRSJ3270Sa&default-theme=true

RNS Number : 3270S  Medpal AI PLC  10 February 2026

10 February 2026

MedPal AI plc

("MedPal AI" or the "Company")

Operational Update: Vertically Integrated UK Healthcare Platform and
Multi-Channel Revenue Model

MedPal AI plc (AIM: MPAL | Frankfurt: Z1N), the AI-powered digital health and
pharmacy services provider, provides this update on its UK vertically
integrated platform. After seizing the opportunity to establish the MedPal
Limited pharmacy operations in October 2025, the Company's strategy has
evolved from being centred on the MedPal app to integrating it with an AI
driven triage system and prescribing service.

The Company's business model uniquely links AI-assisted digital health to
regulated pharmacy and clinical services, generating revenue at every patient
interaction. This creates strong unit economics that improve with scale

Highlights

·      Vertically integrated UK platform is fully operational, merging
AI-powered digital health with human-validated prescribing and robotic
pharmacy dispensing/delivery.

·      Multi-revenue per patient: app subscriptions £3.99/month or
£29.99/year, NHS dispensing fees £9.90+ per item, private prescription
income, and clinical consultation fees.

·      Diverse customer acquisition channels: NHS contracts, DSP
licences, direct ads via MedPal.clinic and app, plus Epassi partnership
accessing 11m+ employees.

·      Bi-directional cross-sell: App users convert to pharmacy
patients; pharmacy patients to app subscribers, boosting lifetime value.

·      Scale demonstrated: 36,951 items dispensed in January 2026; 7,791
app installs, all paid or on Epassi acquisition pathway (no free tier).

 

Integrated Model and Revenue Streams

Core to operations is human-in-the-loop prescribing: AI triage is validated by
professionals, followed by robotic dispensing and delivery. Each patient
potentially yields multiple revenues: recurring app subscriptions , NHS
dispensing fees, private prescriptions (e.g., GLP-1 treatments), and
consultation fees. 36,951prescription items were dispensed in January,
highlighting revenue potential.

Patient Acquisition Channels

Patient growth draws from multiple independent sources for resilience: NHS/DSP
contracts for stable volume; direct ads and MedPal.clinic for private
services; the MedPal app with 7,791 installs (either paid or Epassi-linked);
and Epassi partnerships reaching 11m+ employees, where complimentary access
converts to subscriptions while generating pharmacy revenue.

 

Jason Drummond, CEO of MedPal AI, said:

"MedPal AI's platform uniquely integrates AI, clinicians, and robotic
dispensing for end-to-end care and revenue at every step. Diverse
channels-from NHS contracts to Epassi's 11m+ employees fuel resilient growth.
Our cross-sell flywheel compounds value: app users become pharmacy patients,
and vice versa. With 36,951 items dispensed in January and 7,791 app installs,
we are well positioned for sustained expansion."

 

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUKVURNOUURUR



            Copyright 2019 Regulatory News Service, all rights reserved